JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

JNJ

227.46

-1.06%↓

UNH

369.01

-0.49%↓

TMO

469.28

-1.91%↓

ISRG

457.59

+0.02%↑

ABT

89.51

-1.34%↓

Начало・Списък с акции・Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

81.69 0.88

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

79.4

Максимум

83.29

Ключови измерители
By Trading Economics
Приходи	5.4M -48M
Продажби	6M 57M
Марж на печалбата	-82.974
Служители	414
EBITDA	5.1M -43M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+67.44% upside

Дивиденти
By Dow Jones
Следващи печалби	5.05.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-612M 5.8B
Предишно отваряне	80.81
Предишно затваряне	81.69

Настроения в новините

By Acuity

95%

333 / 347 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

60 / 65.58 Подкрепа & съпротива

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

1.05.2026 г., 21:36 ч. UTC

Придобивния, сливания и поглъщания

FTC Requires 365 Retail Markets to Divest Micromarket Kiosk Business to Clear Acquisition of Cantaloupe

1.05.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Meta Platforms Acquires Humanoid Robot Startup Assured Robot Intelligence

1.05.2026 г., 18:37 ч. UTC

Значими двигатели на пазара

Senseonic Shares Slide on Underwritten Offering Price

1.05.2026 г., 16:46 ч. UTC

Значими двигатели на пазара

Stellantis, Ferrari Fall on Trump Plan to Increase Tariff on European Cars, Trucks

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.05.2026 г., 20:42 ч. UTC

Печалби

Western Digital Beats Earnings Estimates. The Stock Is Falling Anyway. -- Barrons.com

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

1.05.2026 г., 19:33 ч. UTC

Пазарно говорене

Change in Fed Leadership May Hamper Crypto Rebound -- Market Talk

1.05.2026 г., 19:18 ч. UTC

Пазарно говорене

Значими събития в новините

Oil Rises for Second Consecutive Week Amid Middle East Standoff -- Market Talk

1.05.2026 г., 19:13 ч. UTC

Пазарно говорене

Natural Gas Rises as Markets Wait for Warmer Temperatures -- Market Talk

1.05.2026 г., 18:36 ч. UTC

Печалби

3 Takeaways From Apple Earnings. The Stock Is Surging. -- Barrons.com

1.05.2026 г., 18:35 ч. UTC

Печалби

Moderna's Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway. -- Barrons.com

1.05.2026 г., 18:28 ч. UTC

Печалби

These Stocks Are Today's Movers: Apple, Sandisk, Roblox, Intel, Ferrari, Atlassian, Western Digital, Clorox, Paramount Skydance, and More -- Barrons.com

1.05.2026 г., 18:27 ч. UTC

Пазарно говорене

Gold and Silver Higher for the Day, Lower For The Week -- Market Talk

1.05.2026 г., 18:14 ч. UTC

Придобивния, сливания и поглъщания

Barclays Completes Acquisition of Best Egg

1.05.2026 г., 18:04 ч. UTC

Печалби

The First $6 Trillion Company May Not Be Nvidia -- Barrons.com

1.05.2026 г., 17:43 ч. UTC

Пазарно говорене

Home Sales in San Francisco Jump 22.2% in March -- Market Talk

1.05.2026 г., 17:37 ч. UTC

Пазарно говорене

Crypto 'Fear and Greed Index' Returns to Neutral Reading After Brief Dip -- Market Talk

1.05.2026 г., 17:30 ч. UTC

Пазарно говорене

Печалби

Apple's 2Q Print, 3Q Guide Set Up Stock to Outperform -- Market Talk

1.05.2026 г., 17:28 ч. UTC

Пазарно говорене

Печалби

Apple's Shift From Net Cash Neutral Goal Seen as Cryptic Signal -- Market Talk

1.05.2026 г., 17:21 ч. UTC

Пазарно говорене

Печалби

Apple Seen Absorbing Higher Memory Costs -- Market Talk

1.05.2026 г., 17:19 ч. UTC

Пазарно говорене

Значими събития в новините

U.S. Oil Rig Count Rises by 1 to 408 -- Market Talk

1.05.2026 г., 16:38 ч. UTC

Пазарно говорене

Institutional Markets Begin to Trade on Event Contracts -- Market Talk

1.05.2026 г., 16:23 ч. UTC

Придобивния, сливания и поглъщания

Paramount Skydance Gets a Double Upgrade. It's the Warner Bros. Deal. -- Barrons.com

1.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

1.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

1.05.2026 г., 16:15 ч. UTC

Печалби

This AI Stock Is Up 78% This Year. Why It Still Looks Like a Buy. -- Barrons.com

1.05.2026 г., 16:11 ч. UTC

Пазарно говорене

Bank of Canada Committed a 'Messaging Blunder' -- Market Talk

1.05.2026 г., 16:04 ч. UTC

Печалби

Exxon Stock Slips. CEO Warns 'Full Impact' of War is Coming. -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

67.44% нагоре

12-месечна прогноза

Среден 136.23 USD 67.44%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Rhythm Pharmaceuticals Inc през последните 3 месеца.

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Recent bearish events outweigh bullish events.

All events are bullish.

Recent bullish events outweigh bearish events.

Настроение

By Acuity

333 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.